Evaluating the Safety and Effectiveness of Liraglutide in Subjects With Type 2 Diabetes

Novo Nordisk

Status: Completed

Conditions: Diabetes; Diabetes Mellitus, Type 2

Treatments: Drug: liraglutide

Study type: Observational

Funder types: Industry

Identifiers

NCT01403025

U1111-1120-7575 (Other Identifier)

NN2211-3772

JapicCTI-111559 (Registry Identifier)

Details and patient eligibility

About

This trial is conducted in Asia. The aim of the trial is to assess the incidence rate and type of SADRs (serious adverse drug reactions).

Enrollment: 4,121 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subjects with type 2 diabetes mellitus, including newly-diagnosed subjects, who require treatment with liraglutide

Exclusion criteria

• Subjects who are or have previously been on liraglutide
• Subjects who have previously been enrolled in the study
• Subjects with a hypersensitivity to liraglutide or to any of the excipients
• Subjects who are pregnant, breast feeding or have the intention of becoming pregnant within the study periods
• Subjects with cancer (except basal cell skin cancer or squamous cell skin cancer) or any clinically significant disorder, except for conditions associated with type 2 diabetes mellitus history which in the physicians' opinion could interfere with the results of the trial
• Known or suspected abuse of alcohol or narcotics

Trial design

4,121 participants in 1 patient group

Liraglutide

Treatment:

Drug: liraglutide